Development of Gefitinib-Loaded Solid Lipid Nanoparticles for the Treatment of Breast Cancer: Physicochemical Evaluation, Stability, and Anticancer Activity in Breast Cancer (MCF-7) Cells

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Nov 25

PMID 38004415

Authors

Ibrahim A Aljuffali

Md Khalid Anwer

Mohammed Muqtader Ahmed

Ahmed Alalaiwe

Mohammed F Aldawsari

Farhat Fatima

Shahid Jamil

Affiliations

Soon will be listed here.

Abstract

In the current study, the toxic effects of gefitinib-loaded solid lipid nanoparticles (GFT-loaded SLNs) upon human breast cancer cell lines (MCF-7) were investigated. GFT-loaded SLNs were prepared through a single emulsification-evaporation technique using glyceryl tristearate (Dynasan™ 114) along with lipoid 90H (lipid surfactant) and Kolliphore 188 (water-soluble surfactant). Four formulae were developed by varying the weight of the lipoid™ 90H (100-250 mg), and the GFT-loaded SLN (F4) formulation was optimized in terms of particle size (472 ± 7.5 nm), PDI (0.249), ZP (-15.2 ± 2.3), and EE (83.18 ± 4.7%). The optimized formulation was further subjected for in vitro release, stability studies, and MTT assay against MCF-7 cell lines. GFT from SLNs exhibited sustained release of the drug for 48 h, and release kinetics followed the Korsmeyer-Peppas model, which indicates the mechanism of drug release by swelling and/or erosion from a lipid matrix. When pure GFT and GFT-SLNs were exposed to MCF-7 cells, the activities of p53 (3.4 and 3.7 times), caspase-3 (5.61 and 7.7 times), and caspase-9 (1.48 and 1.69 times) were enhanced, respectively, over those in control cells. The results suggest that GFT-loaded SLNs (F4) may represent a promising therapeutic alternative for breast cancer.

Citing Articles

Preparation and Evaluation of Chitosan Coated PLGA Nanoparticles Encapsulating Ivosidenib with Enhanced Cytotoxicity Against Human Liver Cancer Cells.

Alsulays B, Aodah A, Ahmed M, Anwer M Int J Nanomedicine. 2024; 19:3461-3473.

PMID: 38617799 PMC: 11015841. DOI: 10.2147/IJN.S452989.

References

LeFEVRE M, OLIVO R, Vanderhoff J, JOEL D . Accumulation of latex in Peyer's patches and its subsequent appearance in villi and mesenteric lymph nodes. Proc Soc Exp Biol Med. 1978; 159(2):298-302. DOI: 10.3181/00379727-159-40336. View

Md S, Alhakamy N, Alharbi W, Ahmad J, Shaik R, Ibrahim I . Development and Evaluation of Repurposed Etoricoxib Loaded Nanoemulsion for Improving Anticancer Activities against Lung Cancer Cells. Int J Mol Sci. 2021; 22(24). PMC: 8705699. DOI: 10.3390/ijms222413284. View

Gerber D . EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. Drug Dev Res. 2009; 69(6):359-372. PMC: 2701650. DOI: 10.1002/ddr.20268. View

Tomankova K, Polakova K, Pizova K, Binder S, Havrdova M, Kolarova M . In vitro cytotoxicity analysis of doxorubicin-loaded/superparamagnetic iron oxide colloidal nanoassemblies on MCF7 and NIH3T3 cell lines. Int J Nanomedicine. 2015; 10:949-61. PMC: 4321606. DOI: 10.2147/IJN.S72590. View

Gidwani B, Vyas A, Kaur C . Investigation of inclusion behaviour of gefitinib with epichlorohydrin-β-cyclodextrin polymer: preparation of binary complex, stoichiometric determination and characterization. J Pharm Biomed Anal. 2018; 160:31-37. DOI: 10.1016/j.jpba.2018.07.025. View

Kushwaha A, Vuddanda P, Karunanidhi P, Singh S, Singh S . Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. Biomed Res Int. 2013; 2013:584549. PMC: 3817799. DOI: 10.1155/2013/584549. View

Blackledge G, Averbuch S . Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004; 90(3):566-72. PMC: 2409596. DOI: 10.1038/sj.bjc.6601550. View

Alali A, Kalam M, Ahmed M, Aboudzadeh M, Alhudaithi S, Anwer M . Nanocrystallization Improves the Solubilization and Cytotoxic Effect of a Poly (ADP-Ribose)-Polymerase-I Inhibitor. Polymers (Basel). 2022; 14(22). PMC: 9696361. DOI: 10.3390/polym14224827. View

Sharma A, Arora K, Mohapatra H, Sindhu R, Bulzan M, Cavalu S . Supersaturation-Based Drug Delivery Systems: Strategy for Bioavailability Enhancement of Poorly Water-Soluble Drugs. Molecules. 2022; 27(9). PMC: 9101434. DOI: 10.3390/molecules27092969. View

10.

Huang X, Huang J, Leng D, Yang S, Yao Q, Sun J . Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells. World J Surg Oncol. 2017; 15(1):167. PMC: 5577827. DOI: 10.1186/s12957-017-1230-4. View

11.

Alshetaili A . Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines. Saudi J Biol Sci. 2021; 28(9):5065-5073. PMC: 8381081. DOI: 10.1016/j.sjbs.2021.05.025. View

12.

Anwer M, Mohammad M, Ezzeldin E, Fatima F, Alalaiwe A, Iqbal M . Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats. Int J Nanomedicine. 2019; 14:1587-1595. PMC: 6402442. DOI: 10.2147/IJN.S195048. View

13.

El Guerrab A, Bamdad M, Kwiatkowski F, Bignon Y, Penault-Llorca F, Aubel C . Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget. 2016; 7(45):73618-73637. PMC: 5342003. DOI: 10.18632/oncotarget.12037. View

14.

Wang T, Markham A, Thomas S, Wang N, Huang L, Clemens M . Solution Stability of Poloxamer 188 Under Stress Conditions. J Pharm Sci. 2018; 108(3):1264-1271. DOI: 10.1016/j.xphs.2018.10.057. View

15.

Peppas N . 1. Commentary on an exponential model for the analysis of drug delivery: Original research article: a simple equation for description of solute release: I II. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres,.... J Control Release. 2014; 190:31-2. View

16.

Savic R, Luo L, Eisenberg A, Maysinger D . Micellar nanocontainers distribute to defined cytoplasmic organelles. Science. 2003; 300(5619):615-8. DOI: 10.1126/science.1078192. View

17.

Khan Z, Razzaq A, Khan A, Ur Rehman N, Khan H, Khan T . Physicochemical Characterizations and Pharmacokinetic Evaluation of Pentazocine Solid Lipid Nanoparticles against Inflammatory Pain Model. Pharmaceutics. 2022; 14(2). PMC: 8876599. DOI: 10.3390/pharmaceutics14020409. View

18.

Moon D, Kim M, Heo M, Lee J, Choi Y, Kim G . Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells. Arch Pharm Res. 2009; 32(10):1351-60. DOI: 10.1007/s12272-009-2002-7. View

19.

Sherif A, Harisa G, Alanazi F, Nasr F, Alqahtani A . PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer. Int J Nanomedicine. 2022; 17:3287-3311. PMC: 9342893. DOI: 10.2147/IJN.S365974. View

20.

Ahmed M, Anwer M, Fatima F, Aldawsari M, Alalaiwe A, Alali A . Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach. Polymers (Basel). 2022; 14(12). PMC: 9227860. DOI: 10.3390/polym14122459. View